Home›Trial›NCT06433752
NCT06433752RECRUITING

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Study Summary

The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting

Conditions
Relapsing Multiple SclerosisMultiple Sclerosis
Interventions / Drugs
No Intervention
View on ClinicalTrials.gov ↗
Sponsor
TGTX
TG Therapeutics
Oncology
D37/100
Study Details
Enrollment500 participants
Primary Completion—
Lead SponsorTG Therapeutics, Inc.
Data Retrieved2026-04-11 04:29:09.137980+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 500 participants
Sponsor Catalyst Profile

TG Therapeutics (TGTX) is the sponsoring company for this trial. BiotechSign currently grades this company D (37/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

TGTX Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.